RxDoctor Payments Data

Ralph Laraiso, DO

Physical Medicine & Rehabilitation · Prosser, WANPI 1699770842

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $261 and has fallen 70.4% since, to $77 in 2025.

$699in general payments, 2019–2025

Across 18 payments — averaging $38.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$167
  • Nevro Corp.$110
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$109
  • Biodelivery Sciences International, Inc.$73
  • Pfizer$63
  • GRT US Holding, Inc.$45
  • plus $131 from 6 others

What the payments were for

  • Food & beverage$67897%
  • Education$213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$699 in reported general payments places this provider in the 75th percentile of 260 physical medicine & rehabilitation providers in Washington.

See all physical medicine & rehabilitation providers in Washington

Medicare billing

Part B allowed, 2024
$71,586
Medicare patients
69
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate20$10,655
EliquisApixaban11$3,902
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen99$3,268
Gabapentin101$1,376
Lidocaine12$1,277
Oxycodone Hcl63$1,271
Methocarbamol65$1,229
Diclofenac Sodium78$1,057
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen32$923
Pregabalin30$795
Cyclobenzaprine Hcl42$484
Tizanidine Hcl46$415
Atorvastatin Calcium21$404
Tramadol Hcl59$328
Nortriptyline Hcl44$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$3,90211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 260 physical medicine & rehabilitation providers in Washington.

Other physical medicine & rehabilitation in Prosser

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →